Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions

Human Gene Therapy

Volumn 16, Issue 4, 2005, Pages 457-472

  Hughes, Marybeth S ^a   Yu, Yik Y L ^a   Dudley, Mark E ^a   Zheng, Zhili ^a   Robbins, Paul F ^a   Li, Yong ^a   Wunderlich, John ^a   Hawley, Robert G ^b   Moayeri, Morvarid ^b   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELAN A; MONOCLONAL ANTIBODY CD3; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; EFFECTOR CELL; GENE INSERTION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTASIS; MOLECULAR CLONING; NONHUMAN; PERIPHERAL LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR REGRESSION;

ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; GENE TRANSFER TECHNIQUES; GENES, T-CELL RECEPTOR; GENETIC VECTORS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LEUKEMIA, T-CELL; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 20844448391     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.457     Document Type: Article

References (49)

1. BERSET, M., CEROTTINI, J.P., GUGGISBERG, D., ROMERO, P., BURRI, F., RIMOLDI, D., and PANIZZON, R.G. (2001). Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int. J. Cancer 95, 73-77.
2. CHENG, L., DU, C., LAVAU, C., CHEN, S., TONG, J., CHEN, B.P., SCOLLAY, R., HAWLEY, R.G., and HILL, B. (1998). Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. Blood 92, 83-92.
3. CLAY, T.M., CUSTER, M.C., SACHS, J., HWU, P., ROSENBERG, S.A., and NISHIMURA, M.I. (1999). Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163, 507-513.
4. COLIGAN, J.K., KRUISBEEK, A.M., MARGULIES, D.H., SHEVACH, E.M., and STROBER, W. (2001). Current Protocols in Immunology. (John Wiley & Sons, Inc.).
5. CORMIER, J.N., ABATI, A., FETSCH, P., HIJAZI, Y.M., ROSENBERG, S.A., MARINCOLA, F.M., and TOPALIAN, S.L. (1998). Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother. 21, 27-31.
6. DUDLEY, M.E., and ROSENBERG, S.A. (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3, 666-675.
7. DUDLEY, M.E., WUNDERLICH, J., NISHIMURA, M.I., YU, D., YANG, J.C., TOPALIAN, S.L., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., SHERRY, R., LEITMAN, S.F., and ROSENBERG, S.A. (2001). Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363-373.
8. DUDLEY, M.E., WUNDERLICH, J.R., ROBBINS, P.F., YANG, J.C., HWU, P., SCHWARTZENTRUBER, D.J., TOPALIAN, S.L., SHERRY, R., RESTIFO, N.P., HUBICKI, A.M., ROBINSON, M.R., RAFFELD, M., DURAY, P., SEIPP, C.A., ROGERS-FREEZER, L., MORTON, K.E., MAVROUKAKIS, S.A., WHITE, D.E., and ROSENBERG, S.A. (2002a). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854.
9. DUDLEY, M.E., WUNDERLICH, J.R., YANG, J.C., HWU, P., SCHWARTZENTRUBER, D.J., TOPALIAN, S.L., SHERRY, R.M., MARINCOLA, F.M., LEITMAN, S.F., SEIPP, C.A., ROGERS-FREEZER, L., MORTON, K.E., NAHVI, A., MAVROUKAKIS, S.A., WHITE, D.E., and ROSENBERG, S.A. (2002b). A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251.
10. DUDLEY, M.E., WUNDERLICH, J.R., SHELTON, T.E., EVEN, J., and ROSENBERG, S.A. (2003). Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342.
11. FUJIO, K., OKAMOTO, A., TAHARA, H., ABE, M., JIANG, Y., KITAMURA, T., HIROSE, S., and YAMAMOTO, K. (2004). Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. J. Immunol. 173, 2118-2125.
12. HACEIN-BEY-ABINA, S., VON KALLE, C., SCHMIDT, M., LE DEIST, F., WULFFRAAT, N., MCINTYRE, E., RADFORD, I., VILLEVAL, J.L., FRASER, C.C., CAVAZZANA-CALVO, M., and FISCHER, A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256.
13. HANENBERG, H., XIAO, X.L., DILLOO, D., HASHINO, K., KATO, I., and WILLIAMS, D.A. (1996). Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2, 876-882.
14. HARADA, M., LI, Y.F., EL-GAMIL, M., OHNMACHT, G.A., ROSENBERG, S.A., and ROBBINS, P.P. (2001). Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J. Immunother. 24, 323-333.
15. HAWLEY, R.G., LIEU, F.H., FONG, A.Z., and HAWLEY, T.S. (1994). Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1, 136-138.
16. HAWLEY, R.G., LIEU, F.H., FONG, A.Z., GOLDMAN, S.J., LEONARD, J.P., and HAWLEY, T.S. (1996). Retroviral vectors for production of interleukin-12 in the bone marrow to induce a graft-versus-leukemia effect. Ann. N.Y. Acad. Sci. 795, 341-345.
17. HUANG, J., EL-GAMIL, M., DUDLEY, M.E., LI, Y.F., ROSENBERG, S.A., and ROBBINS, P.F. (2004). T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J. Immunol. 172, 6057-6064.
18. JAGER, E., GNJATIC, S., NAGATA, Y., STOCKERT, E., JAGER, D., KARBACH, J., NEUMANN, A., RIECKENBERG, J., CHEN, Y.T., RITTER, G., HOFFMAN, E., ARAND, M., OLD, L.J., and KNUTH, A. (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. U.S.A. 97, 12198-12203.
19. KAWAKAMI, Y., ROSENBERG, S.A., and LOTZE, M.T. (1988). Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168, 2183-2191.
20. KAWAKAMI, Y., DANG, N., WANG, X., TUPESIS, J., ROBBINS, P.F., WANG, R.F., WUNDERLICH, J.R., YANNELLI, J.R., and ROSENBERG, S.A. (2000). Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23, 17-27.
21. KAWAKAMI, Y., WANG, X., SHOFUDA, T., SUMIMOTO, H., TUPESIS, J., FITZGERALD, E., and ROSENBERG, S. (2001). Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J. Immunol. 166, 2871-2877.
22. KESSELS, H.W., WOLKERS, M.C., VAN DEN BOOM, M.D., VAN DER VALK, M.A., and SCHUMACHER, T.N. (2001). Immunotherapy through TCR gene transfer. Nat. Immunol. 2, 957-961.
23. LABRECQUE, N., WHITFIELD, L.S., OBST, R., WALTZINGER, C., BENOIST, C., and MATHIS, D. (2001). How much TCR does a T cell need? Immunity 15, 71-82.
24. LINDEMANN, D., PATRIQUIN, E., FENG, S., and MULLIGAN, R.C. (1997). Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol. Med. 3, 466-416.
25. LIU, K., and ROSENBERG, S.A. (2001). Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356-6365.
26. MACKINNON, S., PAPADOPOULOS, E.B., CARABASI, M.H., REICH, L., COLLINS, N.H., BOULAD, F., CASTRO-MALASPINA, H., CHILDS, B.H., GILLIO, A.P., KERNAN, N.A., et al. (1995). Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86, 1261-1268.
27. MARCHAND, M., WEYNANTS, P., RANKIN, E., ARIENTI, F., BELLI, F., PARMIANI, G., CASCINELLI, N., BOURLOND, A., VANWIJCK, R., HUMBLET, Y., et al. (1995). Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883-885.
28. MORGAN, R.A., COUTURE, L., ELROY-STEIN, O., RAGHEB, J., MOSS, B., and ANDERSON, W.F. (1992). Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20, 1293-1299.
29. MORGAN, R.A., DUDLEY, M.E., YU, Y.Y., ZHENG, Z., ROBBINS, P.F., THEORET, M.R., WUNDERLICH, J.R., HUGHES, M.S., RESTIFO, N.P., and ROSENBERG, S.A. (2003). High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171, 3287-3295.
30. ONODERA, M., YACHIE, A., NELSON, D.M., WELCHLIN, H., MORGAN, R.A., and BLAESE, R.M. (1997). A simple and reliable method for screening retroviral producer clones without selectable markers. Hum. Gene Ther. 8, 1189-1194.
31. ONODERA, M., NELSON, D.M., YACHIE, A., JAGADEESH, G.J., BUNNELL, B.A., MORGAN, R.A., and BLAESE, R.M. (1998). Development of improved adenosine deaminase retroviral vectors. J. Virol. 72, 1769-1774.
32. PADOVAN, E., CASORATI, G., DELLABONA, P., MEYER, S., BROCKHAUS, M., and LANZAVECCHIA, A. (1993). Expression of two T cell receptor alpha chains: Dual receptor T cells. Science 262, 422-424.
33. PAPADOPOULOS, E.B., LADANYI, M., EMANUEL, D., MACKINNON, S., BOULAD, F., CARABASI, M.H., CASTROMALASPINA, H., CHILDS, B.H., GILLIO, A.P., SMALL, T.N., et al. (1994). Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185-1191.
34. PHAN, G.Q., YANG, J.C., SHERRY, R.M., HWU, P., TOPALIAN, S.L., SCHWARTZENTRUBER, D.J., RESTIFO, N.P., HAWORTH, L.R., SEIPP, C.A., FREEZER, L.J., MORTON, K.E., MAVROUKAKIS, S.A., DURAY, P.H., STEINBERG, S.M., ALLISON, J.P., DAVIS, T.A., and ROSENBERG, S.A. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 100, 8372-8377.
35. ROSENBERG, S.A., PACKARD, S.S., AEBERSOLD, P.M., SOLOMON, D., TOPALIAN, S.L., TOY, S.T., SIMON, P., LOTZE, M.T., YANG, J.C., SEIPP, C.A., et al. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676-1680.
36. ROSENBERG, S.A., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., DUDLEY, M.E., SCHWARZ, S.L., SPIESS, P.J., WUNDERLICH, J.R., PARKHURST, M.R., KAWAKAMI, Y., SEIPP, C.A., EINHORN, J.H., and WHITE, D.E. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327.
37. ROSENBERG, S.A., YANG, J.C., and RESTIFO, N.P. (2004). Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915.
38. ROSZKOWSKI, J.J., YU, D.C., RUBINSTEIN, M.P., MCKEE, M.D., COLE, D.J., and NISHIMURA, M.I. (2003). CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J. Immunol. 170, 2582-2589.
39. RUBINSTEIN, M.P., KADIMA, A.N., SALEM, M.L., NGUYEN, C.L., GILLANDERS, W.E., NISHIMURA, M.I., and COLE, D.J. (2003). Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J. Immunol. 170, 1209-1217.
40. RUBIO, V., STUGE, T.B., SINGH, N., BETTS, M.R., WEBER, J.S., ROEDERER, M., and LEE, P.P. (2003). Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9, 1377-1382.
41. SADELAIN, M., RIVIERE, I., and BRENTJENS, R. (2003). Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35-45.
42. SALTER, R.D., HOWELL, D.N., and CRESSWELL, P. (1985). Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21, 235-246.
43. SCHAFT, N., WILLEMSEN, R.A., DE VRIES, J., LANKIEWICZ, B., ESSERS, B.W., GRATAMA, J.W., FIGDOR, C.G., BOLHUIS, R.L., DEBETS, R., and ADEMA, G.J. (2003). Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J. Immunol. 170, 2186-2194.
44. SCHUMACHER, T.N. (2002). T-cell-receptor gene therapy. Nat. Rev. Immunol. 2, 512-519.
45. STANISLAWSKI, T., VOSS, R.H., LOTZ, C., SADOVNIKOVA, E., WILLEMSEN, R.A., KUBALL, J., RUPPERT, T., BOLHUIS, R.L., MELIEF, C.J., HUBER, C., STAUSS, H.J., and THEOBALD, M. (2001). Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2, 962-970.
46. TOPALIAN, S.L., SOLOMON, D., and ROSENBERG, S.A. (1989). Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142, 3714-3725.
47. WALTER, E.A., GREENBERG, P.D., GILBERT, M.J., FINCH, R.J., WATANABE, K.S., THOMAS, E.D., and RIDDELL, S.R. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044.
48. WILLEMSEN, R.A., DEBETS, R., CHAMES, P., and BOLHUIS, R.L. (2003). Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol. 64, 56-68.
49. ZEH, H.J., 3rd, PERRY-LALLEY, D., DUDLEY, M.E., ROSENBERG, S.A., and YANG, J.C. (1999). High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989-994.